TG Therapeutics (NASDAQ:TGTX) Posts Earnings Results, Misses Expectations By $0.26 EPS

Key Points

• TG Therapeutics reported quarterly EPS of $0.05, falling $0.26 short of analysts’ $0.31 consensus estimate and below the $0.17 recorded in the year-ago quarter.
• Despite the earnings miss, quarterly revenue increased 70.2% year over year; the company posted an 88.73% return on equity and a 65.95% net margin.
• Analyst sentiment is mixed but improving, with a consensus “Hold” rating and an average price target of $58.50; five analysts rate the stock a Buy, three a Hold and one a Sell.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) released its quarterly earnings results on Monday. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by ($0.26), Briefing.com reports. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.During the same quarter in the prior year, the company earned $0.17 earnings per share. TG Therapeutics's quarterly revenue was up 70.2% compared to the same quarter last year.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $52.03 on Monday. The company has a market cap of $7.96 billion, a PE ratio of 18.19, a P/E/G ratio of 1.30 and a beta of 1.62. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81. The firm's 50 day moving average price is $50.48 and its 200-day moving average price is $38.94. TG Therapeutics has a 52-week low of $25.28 and a 52-week high of $59.30.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on TGTX shares. Zacks Research raised shares of TG Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday, June 1st. Jefferies Financial Group reissued a "buy" rating and set a $83.00 price objective on shares of TG Therapeutics in a report on Monday, June 22nd. B. Riley Financial lifted their price objective on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a "buy" rating in a research note on Monday, July 27th. HC Wainwright boosted their price objective on TG Therapeutics from $70.00 to $77.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Finally, Weiss Ratings restated a "hold (c+)" rating on shares of TG Therapeutics in a report on Wednesday. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, TG Therapeutics has a consensus rating of "Hold" and an average price target of $58.50.

Institutional Trading of TG Therapeutics

Institutional investors have recently made changes to their positions in the business. Maryland State Retirement & Pension System raised its stake in TG Therapeutics by 2.0% in the fourth quarter. Maryland State Retirement & Pension System now owns 19,899 shares of the biopharmaceutical company's stock valued at $593,000 after buying an additional 393 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in TG Therapeutics by 1.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company's stock worth $1,135,000 after purchasing an additional 441 shares in the last quarter. Smartleaf Asset Management LLC grew its position in TG Therapeutics by 16.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 3,147 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 454 shares during the last quarter. Lido Advisors LLC increased its stake in TG Therapeutics by 3.9% during the 3rd quarter. Lido Advisors LLC now owns 14,276 shares of the biopharmaceutical company's stock valued at $516,000 after purchasing an additional 541 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 573 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.